Ticker Launch
Sign inTry it free

Reverse merger · Pending · CALD

Caldera Therapeutics, Inc.

Reverse merger with Synlogic, Inc. (SYBX)

Caldera Therapeutics, Inc. agreed to merge into Synlogic, Inc. (SYBX), a OTC-quoted biotech that evaluated strategic alternatives, in a reverse merger that takes the private company public. The deal was announced on Jul 29, 2026. The combined company is expected to trade as Caldera Therapeutics, Inc. (CALD) on Nasdaq.

Caldera Therapeutics, Inc. is a clinical-stage biotech developing CLD-423, a TL1A x IL-23p19 bispecific antibody for inflammatory bowel disease, in Phase 1 healthy-volunteer testing in Australia, with Phase 2 trials planned in ulcerative colitis and Crohn's disease.

Status
Pending
Private company
Caldera Therapeutics, Inc.
Public company
Synlogic, Inc. (SYBX)
Public company business before
OTC-quoted biotech that evaluated strategic alternatives
Announced
Jul 29, 2026
Combined company
Caldera Therapeutics, Inc. (CALD)
Exchange
Nasdaq
Sector
Biotech & pharma

More on this deal for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other pending reverse mergers